Cyclooxygenase-2 (Cox-2) expression in lymphomas

Leukemia & Lymphoma
Burhan HazarSibel Hakverdi

Abstract

Lymphoma is a malign disease of the lymphoid system. A variety of risk factors have been described in pathogenesis of disease. We investigated the role of Cyclooxygenase-2 (Cox-2) in malign lymphomas. A total of 52 patients who were admitted to the Oncology Unit of Mersin University with histologically diagnosed lymphoma were enrolled to this study. Ten of the patients had Hodgkin's disease (HD), and 42 had non-Hodgkin's lymphoma (NHL). An immunuhistochemical method was used for Cox-2 expression. Cox-2 expression was detected in 24 of the 42 patients (57%) with NHL, and it was found in seven of the 10 patients (70%) with HD. The mean patient age expressing Cox-2 was 50.2+/-16.6 years and 48.0+/-15.5 years for patients without Cox-2 expression. This difference was not statistically significant (P = 0.660). The overall survival of Cox-2-positive patients was less than for those without Cox-2 expression but the difference was not significant statistically (16.4+/-11.4 vs. 14.7+/-8.2 months, respectively, P = 0.552) in NHL. There was a correlation between Cox-2 and stage of disease. As the stage increased the Cox-2 expression increased (P = 0.037) in NHL. The complete response rate to therapy was significantly higher in Cox-2-negat...Continue Reading

References

Dec 15, 1991·The New England Journal of Medicine·M J ThunC W Heath
Apr 1, 1997·Proceedings of the National Academy of Sciences of the United States of America·M TsujiiR N DuBois
Apr 1, 1998·Journal of the National Cancer Institute·D HwangE Levine
Dec 10, 1998·Journal of Surgical Oncology·K UefujiN Shinomiya
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonG P Canellos
Jun 7, 2000·The Journal of Clinical Investigation·C S WilliamsR N DuBois
Jun 30, 2000·The New England Journal of Medicine·G SteinbachG Kelloff
Mar 13, 2003·American Journal of Epidemiology·Annette B BeiderbeckHubert G M Leufkens
Jun 11, 2003·Progress in Experimental Tumor Research·Stephen Gately, Robert Kerbel
Jul 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N K AltorkiA J Dannenberg
Jul 18, 2003·Lancet·Linda S Evans, Barry W Hancock

❮ Previous
Next ❯

Citations

Jun 23, 2006·Journal of Clinical Pathology·Alexandar TzankovStephan Dirnhofer
Jan 29, 2011·BMC Cancer·Nahum Puebla-OsorioChengming Zhu
Feb 28, 2007·Leukemia & Lymphoma·Semra PaydasGulsah Seydaoglu
Apr 10, 2007·Journal of Comparative Pathology·F L QueirogaC Lopes
Oct 20, 2006·International Journal of Radiation Oncology, Biology, Physics·Su Jung ShimGwi Eon Kim
Feb 14, 2006·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Elizabeth P RyanRichard P Phipps
Sep 28, 2017·Journal of Feline Medicine and Surgery·Jorge Castro-LópezJosep Pastor
Mar 25, 2006·International Journal of Cancer. Journal International Du Cancer·Brian L CohenBal L Lokeshwar
Jun 13, 2019·Pathology Oncology Research : POR·Amen H ZakyMahmoud Rezk
Jan 24, 2020·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Y ElboraiL M Shalaby
Sep 5, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rena BucksteinMichael Crump

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.